New findings explore the adalimumab biosimilar landscape, focusing on formulation, devices, and patient support programs that enhance treatment experiences.
October 2025 marks a transformative period for biosimilars, with new FDA guidelines accelerating approvals and promising significant cost savings for health care.
New clinical data confirms Bmab 1200, a biosimilar to ustekinumab, offers equivalent efficacy and safety for treating ...
UK neurologists release new guidelines for JC virus testing in patients using the natalizumab biosimilar Tyruko, addressing ...
FDA's new guidance streamlines biosimilar development, reducing costs and regulatory hurdles and potentially enhancing market ...
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...
Biosimilars revolutionize health care access in Latin America, offering cost savings and improved treatment availability for ...
A recent study reveals global regulatory inconsistencies in biosimilars, urging convergence to enhance access and savings for patients and health care systems.
A new study confirms that biosimilar ranibizumab matches innovator Lucentis in treating myopic choroidal neovascular membrane ...
A recent study confirms the stability of XSB-001 biosimilar for retinal diseases under realistic clinical handling conditions. Ranibizumab, an anti–vascular endothelial growth factor (VEGF)–A fragment ...
The FDA has approved Celltrion's Eydenzelt, a new aflibercept biosimilar, enhancing treatment options for retinal diseases in the US. The FDA has approved Eydenzelt (aflibercept-boav), an aflibercept ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback